据了解，帝尔激光拟停止使用帝尔转债募集资金投资于"高效太阳能电池激光印刷技术应用研发项目"， 并将剩余募集资金继续存放募集资金专户管理，后续公司将积极筹划、论证合适的投资项目，截至2025 年12月8日，本次拟终止的"高效太阳能电池激光印刷技术应用研发项目"公司募集资金账户余额为3.28 亿元。 帝尔激光曾表示，本次变动的主要原因是近年来光伏行业发展较快，受太阳能电池技术更新、市场周期 波动、国内外光伏行业政策及贸易政策变化等因素的影响，太阳能电池生产行业面临周期性压力，下游 客户资本开支收窄，"高效太阳能电池激光印刷技术应用研发项目"面临的市场需求环境发生变化，为确 保募集资金使用的有效性和必要性，公司拟终止实施该项目。 （文章来源：北京商报） 北京商报讯1月8日晚间，帝尔激光（300776）披露公告称，公司股东会、债券持有人会议审议通过《关 于终止部分募集资金投资项目并将剩余募集资金继续存放募集资金专户管理的议案》。 ...

中国科技出版传媒股份有限公司（证券代码：601858，证券简称：中国科传）于2025年12月29日发布第 四届董事会第十九次会议决议公告，宣布公司董事会审议通过了包括调整及变更部分募集资金投资项 目、使用自有资金支付募投项目部分款项并以募集资金等额置换等多项重要议案。 董事会会议召开情况 公告显示，中国科传第四届董事会第十九次会议通知于2025年12月24日以电子邮件方式发出，会议于 2025年12月29日以通讯表决方式召开。本次会议由董事长胡华强先生召集，应出席董事9名，实际出席 董事9名，会议的召集、召开及表决程序符合《公司法》等相关法律法规及《公司章程》的规定，会议 合法有效。 董事会会议审议情况 会议审议通过了三项议案，具体表决情况如下：审议通过《关于调整及变更部分募集资金投资项目的议 案》，表决结果为9票赞成，0票反对，0票弃权。该议案尚需提交公司股东会审议。审议通过《关于使 用自有资金支付募投项目部分款项并以募集资金等额置换的议案》，表决结果为9票赞成，0票反对，0 票弃权。审议通过《关于召开2026年第一次临时股东会的议案》，表决结果为9票赞成，0票反对，0票 弃权。 对于上述前两项涉及募集资金 ...

证券日报网讯 12月19日晚间，天域生物发布公告称，"天长市龙岗红色古镇文化旅游景区工程总承包项 目"调整后募集资金投资金额为27，570.59万元，截至2025年11月30日，公司已累计投入募集资金21， 648.40万元，投入进度为78.52%。根据本项目当前实施条件现状、公司业务开展以及实际经营资金需 求，为提高募集资金使用效率，经审慎研究，公司拟终止"天长市龙岗红色古镇文化旅游景区工程总承 包项目"，并将剩余尚未使用的募集资金5，967.77万元（含现金管理收益、累计收到的银行利息收入扣 除手续费的净额，实际金额以转出及销户当日募集资金专户中的余额为准）用于永久补充流动资金。本 事项已经公司第五届董事会第五次会议审议通过，尚需提交公司2026年第一次临时股东会审议。 （文章来源：证券日报） ...

格隆汇11月28日丨华新环保(301265.SZ)公布，为提高募集资金使用效率，华新绿源环保股份有限公司 拟将"冰箱线物理拆解、分类收集改扩建项目"及"危险废物处置中心变更项目"终止后剩余募集资金合计 17,929.16万元（暂估金额，含理财收益及利息收入，最终金额以资金转出当日银行专户实际金额为准） 中的12,929.16万元投入到"13.5万吨/年废矿物油加氢精制、1万吨/年乳化液及2.5万吨/年含油包装物处置 利用项目"；5,000万元永久补充流动资金。待资金划转完成后，公司将对原有相关募集资金专户进行销 户处理。 ...

Core Viewpoint - Huanxin Environmental Protection (301265.SZ) announced plans to improve the efficiency of fundraising by reallocating remaining funds from terminated projects to new initiatives [1] Group 1: Fund Allocation - The company intends to allocate a total of 12,929.16 million yuan from the remaining funds of terminated projects to a new project focused on the hydrogenation refining of waste mineral oil, with a capacity of 13.5 tons per year, and the disposal and utilization of 10,000 tons per year of emulsified liquid and 25,000 tons per year of oil-containing packaging [1] - An additional 5,000 million yuan will be permanently allocated to supplement working capital [1] Group 2: Fund Management - After the completion of the fund transfer, the company will proceed to close the original fundraising special account related to the terminated projects [1]

Core Points - Ningbo Jiangfeng Electronic Materials Co., Ltd. held its 28th meeting of the 4th Board of Directors on November 21, 2025, where it approved the proposal for the postponement of fundraising investment projects and adjustments to internal investment structure [1][2] - The meeting was attended by all 9 directors, with 3 present in person and the rest participating via communication [1] - The company plans to adjust the expected usable status dates for three fundraising projects related to semiconductor materials [1][2] Project Adjustments - The projects affected include: - "Annual production of 52,000 ultra-high purity metal sputtering targets for integrated circuits" - "Annual production of 18,000 ultra-high purity metal sputtering target production line renovation project" - "Ningbo Jiangfeng Electronic Semiconductor Materials R&D Center construction project" [1][2] - The adjustments aim to ensure proper implementation of the projects and improve the efficiency of fundraising [2] Compliance and Approval - The adjustments are in line with the company's overall planning and comply with regulations from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the use of raised funds [2] - The proposal received unanimous approval from all board members, with 9 votes in favor and no opposition or abstentions [2]

Group 1 - The company held its second extraordinary general meeting on November 14, 2025, where it approved the cancellation of the supervisory board, increased the number of board seats, and revised the Articles of Association [2][13] - Wang Binchao was elected as the employee director of the third board of directors, with a term lasting until the end of the current board's term [2][5] - The board of directors now consists of 9 members, including 1 employee director, complying with relevant laws and regulations [2][3] Group 2 - The third board of directors' fourth meeting was held on November 14, 2025, where the adjustment of the audit committee members was approved [3][8] - The audit committee now includes Liu Shujin as the chairman, Xu Lin, and Wang Binchao [3][9] - The meeting was attended by all 9 directors, and the resolutions passed were deemed legal and effective [7][8] Group 3 - The company approved an investment of 323.2079 million yuan for the construction of a "High-Precision and Intelligent Pharmaceutical Industrialization Project" through its wholly-owned subsidiary [10] - The project is expected to be completed by April 2028 [10]

Group 1 - The company will hold its second extraordinary general meeting of shareholders in 2025 on September 29, 2025, at 14:30 [3][10] - The meeting will combine on-site and online voting methods, allowing shareholders to participate through the Shenzhen Stock Exchange trading system and internet voting system [4][5] - The record date for shareholders eligible to attend the meeting is September 23, 2025 [6][7] Group 2 - The board of directors approved a proposal to apply for an increase in the comprehensive credit limit of up to RMB 60 million [29][48] - The company plans to use the funds for normal operational needs, including various financial instruments such as bank loans and bills [48] - The board also approved the adjustment of the investment scale for a specific fundraising project, which will now be concluded, and the remaining funds will be permanently supplemented into working capital [39][43]

Core Viewpoint - Shanghai Medicilon Biomedicine Co., Ltd. plans to terminate certain fundraising projects and redirect the remaining funds to new projects, permanently supplement working capital, and continue to store funds in a special account [1][27]. Group 1: Fundraising and Project Termination - The total amount raised by the company as of August 4, 2023, is RMB 1 billion, with a net amount of RMB 985.29 million after deducting fees [7][10]. - The terminated project is the "North Shanghai Biomedicine R&D Innovation Industrial Base Project," which was intended to enhance drug discovery capabilities but is no longer aligned with market demands [11][12]. - The remaining funds of RMB 289.90 million will be allocated as follows: RMB 40 million for increasing capital in MEDICILON USA CORP, RMB 160 million for working capital, and RMB 89.90 million will remain in the special account [12][13]. Group 2: New Project Overview - The new project involves establishing an "Overseas Marketing and R&D Center" in the U.S. to enhance the company's international presence and service capabilities [13][20]. - The project aims to leverage existing overseas sales and R&D teams to expand the company's market influence and improve customer service efficiency [13][19]. - The company has already established a 2,000 square meter R&D office in Boston, which will serve as a strategic hub for this initiative [20][22]. Group 3: Industry Context and Growth Potential - The global pharmaceutical market is expected to grow steadily, driven by increasing R&D investments, with global R&D spending projected to rise from USD 260.6 billion in 2023 to USD 359.2 billion by 2028, reflecting a CAGR of approximately 6.6% [16][17]. - The CRO (Contract Research Organization) industry is experiencing growth, with increasing demand for outsourced R&D services, which is expected to enhance the market penetration of CROs from 49.2% in 2023 to 58.2% by 2028 [20][21]. - The domestic CRO industry is evolving rapidly, with companies actively seeking to expand internationally and improve their service capabilities to meet global standards [17][22].

Meeting Details - The fourth meeting of the ninth Supervisory Board of Ningbo Jintian Copper Industry (Group) Co., Ltd. was held on August 29, 2025, with all three supervisors present, confirming the legality and validity of the meeting procedures [1]. Proposal Review - The Supervisory Board approved the proposal to change part of the fundraising investment projects, specifically altering the original project of "annual production of 70,000 tons of precision copper alloy bars" to "annual production of 10,000 tons of double-zero grade ultra-fine copper conductors" and "450 copper alloy strip production line renovation and upgrade project" [1][2]. - The change involves a total fundraising amount of RMB 266.8593 million, accounting for 18.47% of the total net fundraising amount from the "Jintian Convertible Bonds" [1]. Fund Utilization Plan - The new projects will be implemented by the company's wholly-owned subsidiary, Ningbo Jintian High Conductivity New Materials Co., Ltd. The company plans to provide interest-free loans to the project implementer for the "annual production of 10,000 tons of double-zero grade ultra-fine copper conductors," with a total amount not exceeding RMB 134.8593 million [2]. - The Supervisory Board believes that the changes are necessary adjustments based on the fundraising project situation and the company's operational development plan, which will enhance the efficiency of fundraising utilization [2]. Voting Results - The proposal received unanimous approval with 3 votes in favor, 0 against, and 0 abstentions, and it will be submitted to the shareholders' meeting for further review [3].